Article
CYP2D1 polymorphism in methamphetamine-treated rats: genetic differences in neonatal mortality and effects on spatial learning and acoustic startle.
Neurotoxicology and teratology - 1 Jan 2000
Vorhees C V, Reed T M, Schilling M A, Fisher J E, Moran M S, Cappon G D, Nebert D W
Abstract excerpt
d-Methamphetamine (MA) is one of more than two dozen drugs included in the cytochrome P450-mediated "debrisoquine oxidation polymorphism" panel. The human gene (CYP2D6) is responsible for the "poor metabolizer" (PM) and "extensive metabolizer" (EM) phenotypes for drugs such as MA; a similar polymorphism (the CYP2D1 gene) exists in rats. Female Black or Dark Agouti rats exhibit the PM phenotype, whereas...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
